WEBINARS AND VIDEOS

• Clinical Trial Strategy And ADC Dev Partnership

  As the Bioprocess Online Live panel discussion Accelerating ADC Process Development wraps up, expert panelists Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) address audience questions on AI-driven stratification of patients and biomarkers in clinical patient enrollment and IP strategies and collaboration.

• ADC Heterogeneity, Site-Specific Conjugation

  This busy segment of the Bioprocess Online Live panel discussion Accelerating ADC Process Development finds Dr. Léo Marx (Debiopharm), Dr. Monika Lamba Saini (ADC Therapeutics), and Dr. Philipp Spycher (Araris Biotech) addressing DAR variability and lipophilic toxicity, homogeneity, computational tools to address molecular design and ADC behavior, and revisiting strategic considerations in CDMO selection before addressing a second live poll of our audience. 

• Linker And ADC Platform Manufacturing Technologies

  In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, Dr. Léo Marx (Debiopharm) addresses advances in linker technology before he, Dr. Monika Lamba Saini (ADC Therapeutics) and Dr. Philipp Spycher (Araris Biotech) answer audience questions about the feasibility of developing a platform for ADC development, IP considerations for proprietary technologies, and outsourcing vs. in-house manufacturing approaches.

• Challenges In ADC Process Development

  Where does ADC process development fail? In this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) address audience questions on target identification cleanliness and payload challenges before we turn the tables on the audience with a question on their biggest challenges.

• AI In ADC Target Identification

  How are AI and machine learning contributing to ADC target identification and early development? Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) tackle computational approaches to protein targets, clinical implications of target expression and internalization, and AlphaFold AI-driven pathology in this segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development.

• ADCs & Speed To IND

  In this opening segment from the Bioprocess Online Live panel discussion Accelerating ADC Process Development, expert panelists Dr. Monika Lamba Saini (ADC Therapeutics), Dr. Léo Marx (Debiopharm), and Dr. Philipp Spycher (Araris Biotech) frame up ADC development challenges—including molecular complexity, regulatory and analytical hurdles, and strategic logistical manufacturing. We discuss those challenges in the context of the burgeoning industry’s breakneck development timelines leading up to IND submission.

• Sustainable Manufacturing Through Efficient BioProduction Unit Operations
• Simplify Your Downstream Calculations With Bioprocessing Downstream Calculators

  Simplify complex biopharma downstream processing tasks using a suite of powerful, web-based calculators designed to streamline workflows and automate intricate mathematical modeling.

• Reimagine Sustainability In Bioprocessing

  Achieving sustainability in bioprocessing labs presents distinct challenges. Learn how to reduce your environmental footprint while maintaining efficiency and avoiding extensive re-validation efforts.

• Navigating Global Regulatory Landscapes In An Evolving Biopharma Industry

  Minimize regulatory risks and ensure compliance in the evolving biopharma sector. Watch this on-demand discussion for insights on change management, supplier collaboration, and future market trends.

• Tools For Efficient Downstream Processing Of Antibody-Based Therapeutics

  Watch and discover how to effectively utilize chromatography tools for improved purification of therapeutic monoclonal antibodies and antibody derivatives.

• Process Development With Chromatography Resins And Expert Support

  Watch a Senior Product Manager discuss insights on emerging challenges and advanced downstream purification solutions for biologic therapeutics with chromatography resins, expert knowledge, and dedicated support.

• Efficient Downstream Processing Of Antibody-Based Therapeutics – A CDMO Perspective

  Discover efficient downstream processing strategies for antibody-based therapeutics. Explore key considerations and trade-offs in purity, yield, speed, and cost, from a CDMO perspective.

• Quality Roundtable: Raw Material Planning For Tech Transfer And Scaling Biologics

  Join this roundtable of biopharmaceutical professionals as they share their insights to help you navigate important quality and planning decisions for the progression of your biologic.

• Rapid Process Development And Technical Support For AAV Scaleup

  Accelerate your AAV production journey. Learn how rapid process development and expert support can streamline your path from vial to purified bulk, ensuring scalable and efficient manufacturing.

• mAb Up- And Downstream Process Intensification Strategies

  Discover how to reduce monoclonal antibody (mAb) manufacturing time and costs through process intensification. Learn about continuous perfusion, ultrahigh cell density banks, and more.

• The Role Of Peptones In Boosting Quality And Yield

  Peptones can significantly boost CHO cell bioprocessing. We analyze their impact on diverse CHO cell lines using real-world data to assess their effects on titer, protein quality, and cell growth.

• Analytical Solutions To Help Accelerate Bioprocessing Success

  Unlock the power of data-driven bioprocessing. Discover how advanced analytics can optimize your cell culture process, improve performance, and accelerate success.

• Scalable Production Of Lentivirus For Research To Commercial Manufacturing

  Join our webinar on scaling the CTS LV-MAX System in bioreactors, covering transfection scalability, Thermo S.U.B. advantages, and DynaSpin’s efficient gene therapy integration.

• The Way Forward: Supply Chain Solutions

  Learn how to build a resilient supply chain to navigate today's complex environment. Expert speakers share insights on optimization, innovation, and strategic planning to meet evolving market conditions.

• Innovative Contamination Control: Enabling Integrity And Efficiency

  An integrated approach can enhance contamination control, boost process efficiency, and ensure the production of high-quality cell therapy products.

• The Role of Peptones In Enhancing Efficiency

  Discover how peptones enhance vaccine manufacturing efficiency with valuable insights into cost-effective solutions, variability control in biologically derived materials, and more.

• Outsourcing Considerations For Novel Protein Therapeutics

  Panelists discuss special considerations for outsourcing the development and manufacturing of novel, complex protein therapeutics in this Bioprocess Online Live event.

• Addressing Aggregation And Degradation In Complex Protein Therapeutics

  In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists discuss using a transient expression platform to make fast early product attribute decisions.

• When To Conduct Analytical Assays In Novel Protein Therapeutic Development

  Panelists in the Bioprocess Online Live event discuss the various points at which analytical assays are most critical during complex protein therapeutic development.

• IND Prep Versus Clinical/Commercial Scale-Up In Novel Protein Therapeutics

  In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists share detailed considerations for scale-up of complex protein therapeutics.

• Addressing Post-Translational Modifications In Novel Protein Therapeutics

  Meinhard Hasslacher, Ph.D., Head of CMC at SOTIO Biotech, addresses an audience question on conjugation efficiencies in this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics. From there, we move on to an audience-led discussion on when to initially address titer, PTMS, and product quality during development of novel protein therapeutic cell lines, with Lena Tholen, Ph.D, Director of Cell Line and Bioprocess Development at FyoniBio and Neeraj Pakala, Ph.D. SVP of Product Development and Manufacturing at Vera Therapeutics weighing in.

• Key Attributes To Monitor During Cell Line Development Of Complex Proteins

  In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists discuss key attributes to monitor during cell line development processes.

• Cell Line Selection In Novel Protein Therapeutic Development

  Lena Tholen, Ph.D., and Meinhard Hasslacher, Ph.D., weigh in early on important cell line selection considerations for novel protein therapeutics in this segment of "Early Process Considerations For Novel Protein Therapeutics".

• Three Novel Protein Therapeutic Worldviews

  In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, we meet panelists who share their topline perspectives on developing complex, novel protein therapeutics.

• Maximize Quality Assurance Through Rapid Sterility Testing

  This webinar explores mitigating the risk of product loss, and production delays, as well as the critical role rapid sterility testing plays in ensuring the quality and safety of cell therapy products.

• What's Next For Bioprocess Intensification?

  Experts speaking on Bioprocess Intensification In The Real World wrap up the Bioprocess Online Live event with parting shots and reflections on the current state of process intensification and what the future holds.

• Considerations In Continuous Chromatography

  In this segment of the Bioprocess Online Live event Bioprocess Intensification In The Real World, our presenters discuss considerations for continuous versus batch chromatography and compare notes on the approaches at their respective organizations.

• What Analytics Drive Process Intensification?

  Bioprocess Online Live panelists discuss the most fundamental analytics that inform and enable process intensification strategies in this segment of Bioprocess Intensification In The Real World.

• Process Intensification Development Challenges At AZ and AbbVie

  In this segment of the Bioprocess Online Live event Bioprocess Intensification In The Real World, panelists respond to audience questions about the challenges they’ve encountered while developing process intensification strategies.

• Process Intensification Audience Q&A

  Our panelists take audience questions on process intensification lessons learned from other industries.

• Where Process Intensification Sits In The AbbVie, AstraZeneca Organizations

  In this segment of the Bioprocess Online Live event Bioprocess Intensification In The Real World, panelists discuss where and how their roles in setting the course for process intensification sit within their greater organizations.

• What Bioprocessing Bottlenecks Does Process Intensification Address?

  Supply chains, consumables, and data are identified as three of the management challenges that intensified processes and process automation technology (PAT) are addressing at AbbVie and AstraZeneca.

• Why AstraZeneca and AbbVie Are Intensifying Processes

  In this segment of the Bioprocess Online Live event Bioprocess Intensification In The Real World, our speakers share the motivation for continued process intensification in their respective organizations.

• Accelerating mAb Process Development In The Growing Therapeutics Market

  The market for mAbs and mAb variants is growing rapidly. Explore the latest strategies and advancements in early stage mAb up- and downstream process development.

• Scalable By Design: Streamlining Cell Culture Media Manufacturing

  Learn ways to help improve quality, simplify technology transfer of proprietary media formulations, and mitigate logistical challenges associated with custom media scale-up processes.

• Thermo Fisher Scientific Bio-Expo Live 2024: Downstream Bioprocessing

  Review downstream process tools from Thermo Fisher Scientific to enable optimal biologics purification, including chromatography resins, chemicals, process liquids, and buffers.

• Thermo Fisher Scientific Bio-Expo Live 2024: Upstream Bioprocessing: A Next-Gen Medium And Feed System

  This presentation reviews next-generation cell culture media and feed options and a recent successful scale-up case study done in collaboration with Centre for Biochemical Engineering and Cell Cultivation Techniques at the Zurich University of Applied Sciences.

• Accelerate Process Development With HTS Chromatography Tools

  High Throughput Screening (HTS) chromatography tools can accelerate process development and reduce material usage. Learn about a solution that addresses challenges with their use in new modalities.

• Next-Gen Medium And Feeds System To Improve CHO Cell Line Productivity

  Choose the right CHO medium and feed system to optimize your upstream processes and secure a seamless scaling up.

• Process Liquids And Buffers Offering

  Whether you are a researcher, scientist, or industry professional, this video will provide valuable insights into our large volume liquids manufacturing capabilities.

• Thermo Fisher Scientific Large Volume Liquid Expansion

  This video provides an insightful look into the expansion of the large volume liquids manufacturing site at the Grand Island facility, highlighting the various stages of the manufacturing process and the capabilities it offers to support the bioprocessing industry.

• What Is The DynaChrom™ Single-Use Chromatography System?

  This chromatography system offers a flexible solution, paired with an advanced software platform, allowing easy integration with downstream process automation.

• Quality Roundtable: Optimizing Biologics Manufacturing Processes With Raw Materials

  Improve your commercial manufacturing process with advice from regulatory and raw materials experts on the development journey from pre-clinical to licensure.

• Upstream To Downstream: A Comprehensive Approach To AAV Production

  How can you face the challenges of AAV production, scale up your AAV manufacturing effectively, and enhance the recovery and purity in your downstream processing.